Additionally, a serotonylation-dependent pathway enhanced expression of PD-L1 on cancer cells and restricted tumor immunogenicity,114 suggesting a possible tumor-intrinsic mechanism by which SSRI treatment enhances anti-PD-1 therapy efficacy. This evidence concerns the gene PDCD1 and neoplasm.